Date: 2017-11-15
Type of
information: Initiation of development program
phase: preclinical
Announcement: initiation of development program
Company: Oncodesign (France)
Product: ALK1 kinase inhibitor discovery program
Action
mechanism: Activin receptor-like kinase 1 (ALK1) inhibitor
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On November 15, 2017, Oncodesign announced that it has obtained positive results opening the way for the ALK1 kinase inhibitor discovery program to move on to the lead optimization phase. Activin receptor-like kinase 1 (ALK1) is a kinase involved in angiogenesis. Inhibiting this mechanism is a promising line of research in the quest for new treatments for most types of cancer.
The ALK1 program has produced positive cellular results in a mechanistic model as part of the probe to lead phase. Oncodesign has thus decided to advance it to the lead optimization phase and commence an exhaustive series of in vivo biological tests, while conducting medicinal chemistry optimization of the inhibitor molecules identified. A medicinal chemistry team dedicated to the project will be set up to implement this decision.
Is
general: Yes
